Literature DB >> 7622905

The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease.

M Terai1, K Miwa, T Williams, W Kabat, M Fukuyama, Y Okajima, H Igarashi, S T Shulman.   

Abstract

To detect a causative superantigen and to clarify a possible role for staphylococci in Kawasaki disease (KD), culture supernatants of individual bacterial isolates from 11 acute-stage patients were studied. Toxic shock syndrome toxin-1 (TSST-1) and antibody to TSST-1 and enterotoxins A (SEA), B (SEB), and C (SEC) in acute (mean, day 7) and late convalescent (mean, month 15) sera from 26 patients (12 with coronary artery aneurysms) and 22 age-matched controls were measured. Only 1 of 60 supernatants was mitogenic for human lymphocytes; it was 1 of the 4 Staphylococcus aureus isolates. Mitogenicity was neutralized by sera obtained after administration of intravenous gamma globulin (mean, week 4) but not by late convalescent sera. TSST-1 was detectable in 2 of 26 acute sera and 1 of 22 control sera. No KD but 1 control serum had IgM to TSST-1. IgG seroconversion rates to TSST-1, SEA, SEB, and SEC were 10%, 15%, 21% and 16%, respectively. These data do not support the involvement of toxin-producing staphylococci in KD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622905     DOI: 10.1093/infdis/172.2.558

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease.

Authors:  K Matsubara; T Fukaya; K Miwa; N Shibayama; H Nigami; H Harigaya; H Nozaki; T Hirata; K Baba; T Suzuki; A Ishiguro
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

2.  Immunopathophysiological aspects of an emerging neonatal infectious disease induced by a bacterial superantigen.

Authors:  N Takahashi; H Kato; K Imanishi; K Miwa; S Yamanami; H Nishida; T Uchiyama
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

Review 3.  Pharmacological therapy for patients with Kawasaki disease.

Authors:  R V Williams; L L Minich; L Y Tani
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Decreased interferon-gamma (IFN-gamma)-producing T cells in patients with acute Kawasaki disease.

Authors:  T Matsubara; K Katayama; T Matsuoka; M Fujiwara; M Koga; S Furukawa
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

5.  Production of antibodies to staphylococcal superantigens in atopic dermatitis.

Authors:  D E Campbell; A S Kemp
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

Review 6.  Kawasaki disease. The mystery continues.

Authors:  D J Bradley; M P Glodé
Journal:  West J Med       Date:  1998-01

7.  T cell Vbeta repertoires in childhood vasculitides.

Authors:  P A Brogan; V Shah; A Bagga; N Klein; M J Dillon
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

8.  The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies.

Authors:  E Grunebaum; M Blank; S Cohen; A Afek; J Kopolovic; P L Meroni; P Youinou; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

Review 9.  Kawasaki syndrome.

Authors:  A H Rowley; S T Shulman
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

Review 10.  Kawasaki disease: an update.

Authors:  Abraham Gedalia
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.